HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
27 hedge funds and large institutions have $13.3M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 22 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
11% less capital invested
Capital invested by funds: $15M → $13.3M (-$1.66M)
39% less funds holding
Funds holding: 44 → 27 (-17)
77% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$1.53M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$211K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$131K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
| 5 |
First Manhattan
New York
|
+$75.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.83M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$922K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$776K |
| 4 |
SCM
Sio Capital Management
New York
|
-$199K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$179K |
HTGM Hedge Fund Activity: Q4 2019 in Review
27 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2019, worth a combined $13.3M — down 11% from $15M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of HTGM and 5 opened new positions — a net loss of 17 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Cowen Prime Advisors, adding an estimated $1.53M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.83M sold.
- 27 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2019, down from 44 in Q3 2019.
- Funds reported $13.3M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2019, down 11% quarter-over-quarter.
- 5 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2019 and 22 closed out, a net change of -17 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2019 was Cowen Prime Advisors, an estimated $1.53M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2019 was Fidelity Investments, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2019.